No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
GBIO240719C2500
- 0.05
- -0.60-92.31%
15min DelayClose Jul 19 15:59 ET
0.42High0.05Low
0.42Open0.65Pre Close38 Volume46 Open Interest2.50Strike Price1.04KTurnover0.00%IV-11.46%PremiumJul 19, 2024Expiry Date0.38Intrinsic Value100Multiplier-1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma57.60Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
News
Generation Bio(GBIO.US) Officer Sells US$18,410.06 in Common Stock
$Generation Bio(GBIO.US)$ Officer Paone Antoinette sold 6,719 shares of common stock on Jul 1, 2024 at an average price of $2.74 for a total value of $18,410.06.Source: Announcement What is statement
Insiders At Generation Bio See Good Returns After Buying Stock Worth US$778.9k
Insiders who bought Generation Bio Co. (NASDAQ:GBIO) stock lover the last 12 months are probably not as affected by last week's 23% loss. After taking the recent loss into consideration, the US$778.9
Generation Bio to Present at the 2024 TD Cowen Genetic Medicines & RNA Summit
CAMBRIDGE, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff
JMP Securities Maintains Generation Bio(GBIO.US) With Hold Rating
JMP Securities analyst Silvan Tuerkcan maintains $Generation Bio(GBIO.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 36.4% and a total average return of 4.1% ove
Analysts' Opinions Are Mixed on These Healthcare Stocks: Generation Bio (GBIO), LAVA Therapeutics (LVTX) and Aura Biosciences Inc (AURA)
Generation Bio Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Sales Results.
Generation Bio Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Sales Results.
Comments
$Generation Bio(GBIO.US$
NEWS
Generation Bio Announces the Presentation of Preclinical Data on iqDNA and ctLNP Platforms at the ASGCT 27th Annual Meeting
Positive
Generation Bio's presentation at the ASGCT highlights significant advancements in iqDNA technology and ctLNP delivery systems, showcasing the company's commitment to innovation in genetic medicine.
The rapid enzymatic synthesis process utilized by Generation Bio enhances the performance of iqDNA, providing a potential breakthrough in ...
NEWS
Generation Bio Announces the Presentation of Preclinical Data on iqDNA and ctLNP Platforms at the ASGCT 27th Annual Meeting
Positive
Generation Bio's presentation at the ASGCT highlights significant advancements in iqDNA technology and ctLNP delivery systems, showcasing the company's commitment to innovation in genetic medicine.
The rapid enzymatic synthesis process utilized by Generation Bio enhances the performance of iqDNA, providing a potential breakthrough in ...
$Generation Bio(GBIO.US$
NEWS
Generation Bio Announces the Acceptance of Five Abstracts and an Invited Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
Generation Bio Co. will present six abstracts at the ASGCT 27th Annual Meeting.
The abstracts will highlight preclinical data from the company's ctLNP and iqDNA platforms.
One of the presentations will focus on highly specific, in vivo delivery to T-cells with cell-targeted lipid nanoparticles.
The c...
NEWS
Generation Bio Announces the Acceptance of Five Abstracts and an Invited Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
Generation Bio Co. will present six abstracts at the ASGCT 27th Annual Meeting.
The abstracts will highlight preclinical data from the company's ctLNP and iqDNA platforms.
One of the presentations will focus on highly specific, in vivo delivery to T-cells with cell-targeted lipid nanoparticles.
The c...
+1
2
1
Read more